Clinical data | |
---|---|
Trade names | Seconal, others |
Other names | Quinalbarbitone |
AHFS/Drugs.com | Consumer Drug Information |
MedlinePlus | a682386 |
Pregnancy category |
|
Routes of administration | By mouth, intravenous |
Drug class | Barbiturate |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | ? |
Protein binding | 45-60%[2] |
Metabolism | Hepatic |
Elimination half-life | 15-40 hours[2] |
Excretion | Renal |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.000.894 |
Chemical and physical data | |
Formula | C12H18N2O3 |
Molar mass | 238.287 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Secobarbital, sold under the brand name Seconal among others, is a short-acting barbiturate drug originally used for the treatment of insomnia. It was patented by Eli Lilly and Company in 1934 in the United States.[3] It possesses anesthetic, anticonvulsant, anxiolytic, sedative, and hypnotic properties. In the United Kingdom, it was known as quinalbarbitone. Secobarbital is considered to be an obsolete sedative-hypnotic (sleeping pill) and has largely been replaced by the benzodiazepine family. It was widely abused, known on the street as "red devils" or "reds."[4] Among barbiturates, secobarbital carries a particularly high risk of abuse and addiction, which is largely responsible for it falling out of use.